Table 1 Survival analysis based on clinical and demographical covariates. Hazard ratio, confidence interval (95%) and p-values for clinical and treatment covariates for GBM patients (n = 502)
Covariate 1Hazard ratio (95% CI)2Pr(>|z|)3
Age at diagnosis1.029 (1.020,1.038)< 0.0001
Gender (male)1.064 (0.859, 1.319)0.5684
Race (European-American)1.128 (0.709, 1.795)0.6119
Method of diagnosis (tumor resection)1.194 (0.877, 1.625)0.2591
Temozolomide0.641 (0.496, 0.828)0.0007
Bevacizumab0.317 (0.078, 1.281)0.1069
Radiation0.918 (0.612, 1.377)0.6793
Temozolomide + bevacizumab2.731 (0.644, 11.576)0.1727
Temozolomide + radiation0.839 (0.483, 1.459)0.5360
Bevacizumab + radiation0.463 (0.181, 1.187)0.1089
  • 1 Clinical covariates included in the model; 2Hazard ratio and corresponding 95% confidence interval; 3p-value for significance of the covariate.